Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Licenses Epigentek IP for Upcoming Epigenetic Product Line

NEW YORK (GenomeWeb News) — Sigma-Aldrich today said it has licensed from Epigentek technology for DNA modification, methylation quantitation, and protein/DNA interaction, which Sigma plans to use to develop its planned epigenetics research products.
 
The license is exclusive in the US and co-exclusive globally, Sigma-Aldrich said.
 
Keith Jolliff, Sigma-Aldrich’s director of Genomics and Functional Genomics, said the agreement “is an excellent entry point to supporting epigenetics research,” which he said the company has identified “as a growing area of interest and research for heritable diseases such as cancer, Alzheimer’s, and many others.”
 
Sigma-Aldrich plans to launch a family of products for epigenetic research, beginning with the Imprint DNA Modification Kit, which it will launch this month. Other products planned under the Imprint brand include kits for global methylation quantitation and chromatin immunoprecipitation based on Epigentek's technologies.
 
Financial terms of the agreement were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.